A randomized phase IIb study of AIO German Gastric Cancer Group and Swiss SAKK (DANTE Trial) compared FLOT + atezolizumab versus FLOT in patients with resectable esophagogastric adenomarcinoma (20), the interim result showed “beneficial effects of atezolizumab combined with FLOT vs. FLOT alone on pathological stage and pathological regression that seem to be more pronounced with higher PD‐L1 expression”. This evidence concerns the gene CD274 and gastric cancer.